Adiposopathy · ASCVD screening protocol
Adiposopathy and ASCVD: A Treat-Obesity-First Screening Protocol for Primary Care
Screen adiposopathy the way you screen any cardiovascular risk factor: by measurement, not by BMI. A treat-obesity-first protocol pairs waist and body composition with vascular (ankle-brachial index, arterial stiffness), autonomic (heart rate variability, cardiac autonomic reflex tests) and laboratory markers of sick fat, then treats the adipose tissue itself instead of chasing each downstream number.
Most primary care visits treat obesity as a background condition and its consequences as the work: titrate the antihypertensive, add the second diabetes drug, recheck the lipids. The 2026 Obesity Medicine Association statement asks for the order to be reversed. This is a practical version of what that looks like on a Tuesday afternoon.
What does the 2026 OMA statement change?
The statement frames obesity as a chronic disease that causes cardiovascular disease directly, through biomechanical “fat mass disease” and dysfunction of epicardial adipose tissue, and indirectly, through adiposopathic immune and endocrine abnormalities that drive type 2 diabetes, hypertension, dyslipidemia and thrombosis. Its management conclusion is a shift “from treating downstream risk factors to addressing excessive adipose tissue itself,” which it calls treat obesity first, and it recommends precision diagnostics as part of that approach.
The underlying concept, adiposopathy, also explains why risk does not track fat mass neatly. Judging adipose tissue by function rather than quantity resolves most of the obesity paradoxes. For screening, that means the question is not “how heavy” but “how sick,” and BMI cannot answer it.
What do SELECT, STEP-HFpEF and SUMMIT add to the case?
Three randomized trials now connect treating adipose tissue to hard or patient-centered cardiovascular outcomes.
- SELECT enrolled 17,604 adults aged 45 and older with established cardiovascular disease, BMI 27 or higher and no diabetes. Over a mean follow-up of 39.8 months, the primary outcome of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 6.5% on semaglutide 2.4 mg weekly versus 8.0% on placebo (HR 0.80, 95% CI 0.72 to 0.90). Adverse events leading to discontinuation were 16.6% versus 8.2%.
- STEP-HFpEF randomized 529 patients with HFpEF and BMI 30 or higher. At 52 weeks, KCCQ clinical summary score improved 16.6 versus 8.7 points, body weight changed by -13.3% versus -2.6%, 6-minute walk distance by 21.5 m versus 1.2 m, and CRP by -43.5% versus -7.3%. Serious adverse events were 13.3% versus 26.7%.
- SUMMIT randomized 731 patients with HFpEF and BMI 30 or higher to tirzepatide or placebo over a median 104 weeks. Cardiovascular death or worsening heart failure occurred in 9.9% versus 15.3% (HR 0.62, 95% CI 0.41 to 0.95), driven by worsening heart-failure events (8.0% versus 14.2%). Cardiovascular death alone was 2.2% versus 1.4%, with a wide interval that does not support a conclusion either way.
Read the populations before applying the results. SELECT excluded diabetes and required established disease; both HFpEF trials required BMI 30 or more. None enrolled the multimorbid chronic-pain patient on several sedating medications who fills many primary care panels. The signal is consistent: reduce the adipose tissue and its inflammatory output and cardiovascular outcomes move. The plan for each patient is still built from that patient’s measurements.
Who should be screened?
Start from the criteria in who to test: adults over 50 with any cardiovascular risk factor, everyone over 70, and anyone with hypertension, overweight, diabetes or a smoking history. Add three groups the usual criteria miss:
- Normal BMI with central adiposity. Waist adds risk information at every BMI level, and a consensus group has asked that it be recorded as a vital sign.
- Chronic pain. In the UK Biobank, chronic widespread pain carried an adjusted HR of 1.48 for composite cardiovascular disease.
- Peripheral neuropathy, which shares the inflammatory terrain and predicts mortality. The evidence is in neuropathy and chronic pain as cardiovascular risk markers.
Expect a high yield. On NHANES 2009–2016 criteria, under 12.2% of US adults were metabolically healthy, and among adults with obesity the figure was 0.5%. On tighter cardiometabolic criteria, NHANES 2017–2018 put it under 7%. That is the general population, not a referral clinic’s.
Which measurement maps to which pathway?
Fat mass disease
Bioimpedance body composition separates fat mass, lean mass and trunk fat, and flags the sarcopenic patient whose BMI understates risk. Indirect calorimetry gives a measured resting energy expenditure and respiratory quotient to build nutrition therapy from. Screen symptomatically for sleep apnea in parallel; the OMA statement treats it as a cardiovascular comorbidity of obesity.
Sick fat disease
Ankle-brachial index: in the ABI Collaboration’s 16 cohorts, an ABI of 0.90 or below roughly doubled 10-year total and cardiovascular mortality within every Framingham category and reclassified about 19% of men and 36% of women. Arterial stiffness and endothelial function: in the aortic PWV literature, each 1 m/s increment carried a 14% higher adjusted risk of cardiovascular events. The Measura index is oscillometric with PPG contour analysis, not carotid-femoral PWV; treat it as related evidence and trend it within the patient.
Laboratory, in the order the derangement usually appears: LP-IR (rises before HbA1c), fasting insulin reported on its own and as HOMA-IR (the Padda Institute treats fasting insulin above 10 µIU/mL as high risk), GGT (risk cutoff above 20 U/L in the same clinic), oxidized LDL with the omega-3 index and omega-6 to omega-3 ratio, hs-CRP against the 1 and 3 mg/L bands, 25-OH vitamin D, homocysteine, and B12 with MMA or holotranscobalamin. See laboratory panels.
The autonomic layer
Heart rate variability and cardiac autonomic reflex tests detect cardiovascular autonomic dysfunction, which carries its own mortality signal, and sudomotor testing screens small-fiber involvement. Use a battery rather than a single index; the mortality association is far stronger when two or more abnormalities define the diagnosis.
How does this fit into standing orders and documentation?
Write the screen as a standing order triggered by the criteria above, run by trained technicians, with results returned to the ordering physician for interpretation. The templates are in standing orders, and reading the combined report is covered in interpreting the report. Re-measure after a meaningful change in weight or therapy so the patient sees the terrain respond, not just the scale. Body composition, BMI follow-up plans and cardiovascular risk assessment also support documentation for the annual wellness visit and quality reporting; see MIPS and quality reporting.
Where does pharmacotherapy fit?
GLP-1 receptor agonists and dual agonists have the outcome data above and may be part of the solution for specific patients, selected after the evaluation and monitored with the same measurements. They do not replace the behavioral work, which at the Padda Institute is 40 to 50% of the treatment protocol: lower acellular carbohydrate intake, removing industrial seed oils, protein and resistance training to prevent sarcopenic wasting during weight loss, sleep, and the social isolation that drives eating. On lipid therapy, interpret statin trials in the populations they enrolled and individualize in multimorbid patients rather than defaulting to dose escalation.
Dr. Padda spent years telling patients with prediabetes that their A1c was fine. It was, by the cutoff. Their insulin, their liver and their nerves were not. That is the failure this protocol is built to prevent: a reassuring threshold standing in for a measurement nobody took.
Frequently asked questions
Should screening wait until BMI reaches 30?
No. Waist circumference adds risk information at every BMI level, and central adiposity with insulin resistance is common at a normal BMI. That is why the screening trigger should be a measurement, not a BMI cutoff.
Does an abnormal ABI or stiffness index change management if lipids are controlled?
It changes the risk estimate. A low ABI reclassified roughly a fifth of men and a third of women in pooled cohorts. It strengthens the case for treating adiposity and insulin resistance aggressively and for re-measuring to confirm the vascular findings move.
Build the protocol into your clinic
We help practices set up standing orders, technician workflow and report interpretation for cardiometabolic and autonomic testing.
4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.
References
- Bays, H. E., Varney, C., Alexander, L., Ng, J., Tondt, J., Weber, C., et al. (2026). Obesity and Cardiovascular Disease: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2026. Obesity Pillars, 20, 100283. https://doi.org/10.1016/j.obpill.2026.100283 (PMID 42729919)
- Bays, H. E. (2011). Adiposopathy is “sick fat” a cardiovascular disease?. Journal of the American College of Cardiology, 57(25), 2461-2473. https://doi.org/10.1016/j.jacc.2011.02.038 (PMID 21679848)
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221-2232. https://doi.org/10.1056/NEJMoa2307563 (PMID 37952131)
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., et al. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 389(12), 1069-1084. https://doi.org/10.1056/NEJMoa2306963 (PMID 37622681)
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., et al. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 392(5), 427-437. https://doi.org/10.1056/NEJMoa2410027 (PMID 39555826)
- Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., et al. (2020). Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nature Reviews Endocrinology, 16(3), 177-189. https://doi.org/10.1038/s41574-019-0310-7 (PMID 32020062)
- Rönnegård, A.-S., Nowak, C., Äng, B., & Ärnlöv, J. (2022). The association between short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease in the UK Biobank. European Journal of Preventive Cardiology, 29(15), 1994-2002. https://doi.org/10.1093/eurjpc/zwac127 (PMID 35727954)
- Araújo, J., Cai, J., & Stevens, J. (2019). Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009-2016. Metabolic Syndrome and Related Disorders, 17(1), 46-52. https://doi.org/10.1089/met.2018.0105 (PMID 30484738)
- O’Hearn, M., Lauren, B. N., Wong, J. B., Kim, D. D., & Mozaffarian, D. (2022). Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. Journal of the American College of Cardiology, 80(2), 138-151. https://doi.org/10.1016/j.jacc.2022.04.046 (PMID 35798448)
- Collaboration, A. B. I., Fowkes, F. G. R., Murray, G. D., Butcher, I., Heald, C. L., Lee, R. J., et al. (2008). Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA, 300(2), 197-208. https://doi.org/10.1001/jama.300.2.197 (PMID 18612117)
- Vlachopoulos, C., Aznaouridis, K., & Stefanadis, C. (2010). Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. Journal of the American College of Cardiology, 55(13), 1318-1327. https://doi.org/10.1016/j.jacc.2009.10.061 (PMID 20338492)
- Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., et al. (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3), 499-511. https://doi.org/10.1161/01.cir.0000052939.59093.45 (PMID 12551878)
- Maser, R. E., Mitchell, B. D., Vinik, A. I., & Freeman, R. (2003). The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care, 26(6), 1895-1901. https://doi.org/10.2337/diacare.26.6.1895 (PMID 12766130)
Related reading
- Neuropathy and Chronic Pain as Cardiovascular Risk Markers
- Visceral Adiposity: Screening for the Risk That BMI Misclassifies
- Standing Orders
Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed .